Clinical Significance Of MRNA Expression Of MET Gene In Non-small Cell Lung Cancer:an Analysis Of 48 Cases

Objective To detect the mRNA expression of MET gene in untreated NSCLC patients, investigate the relationship and clinical significance between mRNA expression of MET gene, clinical factors and downstream signaling pathways.Method 48 untreated NSCLC patients in PLA general hospital from June 2011 to November 2013 were selected. The branched DNA liquid chip technology was used to detect mRNA expression of MET gene in tumor tissues. Clinical data and progression of NSCLC were collected. The relationship between mRNA expression of MET gene, clinical factors and PI3K/Akt/mTOR signaling pathway was analyzed by statistic method.Result In 48 cases, constituent ratios of low, moderate and high mRNA expression level of MET gene were 22.9%,50.0% and 27.1% respectively. There were significant differences in pathology type between different mRNA expression levels of MET gene (p<0.05), and mRNA expression of MET gene was correlated to pathology type (r=-0.373,p<0.01). mRNA expressions of MET, PI3KCA and Aktl gene were correlated to each other (r=0.292, p<0.05; r=0.433, p<0.01; r=0.398, p<0.01), suggested that MET, PI3KCA and Aktl gene showed co-expression. The progression-free survival time was correlated to differentiation degree (p<0.05), lymph node metastasis (p<0.01), distant metastasis (p<0.01), TNM stage (p<0.01) and mRNA expressions of MET and Aktl gene (p<0.05). The multivariate analysis showed that distant metastasis (RR=28028.697, p<0.01) and high mRNA expression level of MET gene (RR=573.251, p<0.01) were indenpend risk factors for progression-free survival.Conclusion mRNA expression of MET gene has higher level in NSCLC patients with adenocarcinoma. MET gene may be involved in the process of NSCLC tumorigenesis through PICK/Akt/mTOR signaling pathway. High mRNA expression level of MET gene may be a valuable biomarker for prognosis.